Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Molecule Stops E. Coli From Releasing Toxins

By R&D Editors | March 29, 2010

Pathogenic bacteria in the gut recognise their surroundings by detecting hormone signals from the host, which can prompt them to express lethal toxins. Intercepting these hormonal messages could be a better way to treat serious food-borne infections where antibiotics do more harm than good, explains Vanessa Sperandio speaking at the Society for General Microbiology’s spring meeting in Edinburgh today.

Gut bacteria, including harmful strains of Escherichia coli and Salmonella that cause food poisoning, detect and respond to adrenaline released by the host, through a sensor called QseC embedded in the bacterial surface. When adrenaline binds to QseC, it is like toppling the first tile of a complex domino arrangement – it triggers a chain of events that can ultimately result in the production of toxins.

Dr Sperandio’s group at the University of Texas Southwestern Medical Center have identified a molecule, called LED209, which stops adrenaline binding to QseC. Blocking binding prevents the signalling events inside the bacterium, reducing toxin production and also hindering bacteria from attaching effectively to the epithelial cells that line the gut. When given orally to infected mice, LED209 was found to reduce the number of gut-colonising Salmonella.

The discovery could represent the first of a novel class of antimicrobial agents. “QseC is a very attractive drug target because it is present in at least 25 important animal and plant pathogens but not in mammals. This means that drugs targeting this sensor are less likely to be toxic and have the potential to be broad-spectrum (effective against several types of infection).”

Alternative treatments are needed for pathogenic E. coli and Salmonella infections, as antibiotic treatment can make the illness worse, explained Dr Sperandio. “Conventional antibiotics can trigger the SOS response in bacteria that actually enhances virulence. LED209, unlike antibiotics, does not kill or hinder E. coli growth and consequently does not promote expression of shiga toxin – which is the bacterium’s defence mechanism. Instead, LED209 decreases expression of genes that encode this toxin,” she said. “What is more, because this signalling system does not directly influence bacterial growth, inhibiting it may not exert a strong selective pressure for the development of resistance.”

Date: March 28, 2010
Source: Society for General Microbiology

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE